PhenomeX Inc. (Nasdaq: CELL), the practical cell biology firm, immediately introduced the launch of .
The Opto B Discovery workflows, with their cutting-edge applied sciences and options, allow scientists to search out lead candidate antibodies tailor-made to their particular challenges and altering wants. Mixed with the value-matched Beacon Choose system, extra prospects might entry these propriety antibody discovery functions, however with the optimum degree of options that meet their analysis and budgetary wants. PhenomeX’s optofluidic platform is now an ordinary to ship optimum antibodies with velocity, as highlighted not too long ago within the high-impact journal , the place antibodies towards COVID-19 variants had been found on the Beacon system six months earlier than Omicron emergence.
Beacon Choose for Antibody Discovery Workflow Characteristic
Opto B Discovery workflows on the Beacon Choose system allow scientists to speed up antibody screening and hit era to search out lead candidate antibodies and are ideally fitted to small- to mid-sized biopharma and CDMOs/CROs. This contrasts with the flagship four-chip Beacon system enabled for antibody discovery, optimized for the very best screening throughputs demanded by giant biopharma and established CDMOs/CROs.
The Beacon Choose system permits fast function-first choice of single B cells with the most effective traits for any antibody software, together with antibody therapeutics, diagnostics, and . As well as, the Opto B Discovery workflows supply customers extremely customizable assays to evaluate and epitope specificity, species or variant cross-reactivity, and practical properties, all in a single-day workflow. By choosing and recovering sequences of solely essentially the most fascinating antibodies with favorable attributes, customers can scale back total bioprocessing prices, enhance the likelihood of marketing campaign success, and shorten timelines to guide candidates. When mixed with PhenomeX’s catalog of best-in-class reagents and consumables for mouse, human, and rabbit B cell repertoires, prospects can do all this towards even the toughest antigen targets, together with G coupled-protein receptors (GPCRs) and ion channels, to speed up antibody discovery past conventional strategies out there immediately.
To additional improve buyer accessibility and affordability, PhenomeX will supply the Beacon Choose system for antibody discovery with completely different buy choices together with capital placement, lease, or reagent rental. The 2-chip Beacon Choose record value will probably be roughly half of the present Beacon system, which makes the expertise perfect for brand spanking new customers that don’t want the complete Beacon capability. As well as, this lower cost level permits current Beacon prospects to extra readily improve throughput, add laboratory capability, and (for current cell line growth prospects) entry antibody discovery functions.
PhenomeX participation at 19th Annual PEGS Boston Convention & Expo
PhenomeX is taking part on the 19th annual Protein Engineering & Cell Remedy Summit (PEGS) convention and expo being held from Could 15-19 on the Hynes Conference Middle in Boston, Mass. On the convention, the Firm will characteristic its optofluidic and proteomic platform applied sciences, together with the brand new Beacon Choose system, in sales space #517 and current two posters and podium displays. Attendees can discover demonstrations of the expertise and study extra about how PhenomeX’s merchandise can advance and speed up our understanding of mobile operate alongside the continuum of scientific discovery, bioprocessing, scientific analysis, and immunotherapy growth.
Learn extra concerning the PhenomeX expertise posters and podium displays being shared at PEGS at .